Original language | English |
---|---|
Article number | 89 |
Journal | Blood cancer journal |
Volume | 11 |
Issue number | 5 |
DOIs | |
State | Published - May 2021 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. / Mikhael, Joseph; Belhadj-Merzoug, Karim; Hulin, Cyrille; Vincent, Laure; Moreau, Philippe; Gasparetto, Cristina; Pour, Ludek; Spicka, Ivan; Vij, Ravi; Zonder, Jeffrey; Atanackovic, Djordje; Gabrail, Nashat; Martin, Thomas G.; Perrot, Aurore; Bensfia, Samira; Weng, Qilong; Brillac, Claire; Semiond, Dorothée; Macé, Sandrine; Corzo, Kathryn P.; Leleu, Xavier.
In: Blood cancer journal, Vol. 11, No. 5, 89, 05.2021.Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
AU - Mikhael, Joseph
AU - Belhadj-Merzoug, Karim
AU - Hulin, Cyrille
AU - Vincent, Laure
AU - Moreau, Philippe
AU - Gasparetto, Cristina
AU - Pour, Ludek
AU - Spicka, Ivan
AU - Vij, Ravi
AU - Zonder, Jeffrey
AU - Atanackovic, Djordje
AU - Gabrail, Nashat
AU - Martin, Thomas G.
AU - Perrot, Aurore
AU - Bensfia, Samira
AU - Weng, Qilong
AU - Brillac, Claire
AU - Semiond, Dorothée
AU - Macé, Sandrine
AU - Corzo, Kathryn P.
AU - Leleu, Xavier
N1 - Funding Information: The study was sponsored by Sanofi. The authors thank the participating patients and their families, and the study centers and investigators, for their contributions to the study. Medical writing support was provided by Camile Semighini Grubor, PhD, of Elevate Medical Affairs, contracted by Sanofi Genzyme for publication support services.
PY - 2021/5
Y1 - 2021/5
UR - http://www.scopus.com/inward/record.url?scp=85105788793&partnerID=8YFLogxK
U2 - 10.1038/s41408-021-00478-4
DO - 10.1038/s41408-021-00478-4
M3 - Letter
C2 - 33980831
AN - SCOPUS:85105788793
VL - 11
JO - Blood Cancer Journal
JF - Blood Cancer Journal
SN - 2044-5385
IS - 5
M1 - 89
ER -